The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Thiotepa-containing regimens for PCNSL patients undergoing autoHCT
Trent Wang, DO, MPH, Sylvester Comprehensive Cancer Center, Miami Springs, FL, discusses the role of thiotepa-containing conditioning regimens in patients with primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS) who are undergoing autologous hematopoietic cell transplantation (autoHCT). Primary CNS lymphoma (PCNSL) is a rare non-Hodgkin lymphoma, and no studies have been conducted to determine the optimal conditioning regimen for these patients. Thiotepa plus busulfan and cyclophosphamide (TBC), thiotepa plus carmustine (TT-BCNU), and BCNU/etoposide/cytarabine/melphalan (BEAM) are common regimens, so a retrospective analysis of over 600 patients was carried out to compare outcomes for PCNSL patients receiving these treatments. When 3-year progression free survival was investigated, TBC and TT-BCNU were found to give superior results to BEAM. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
